VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
---|---|---|---|---|---|---|---|---|
TVIS10014315 | HBV | ENSG00000081248.13 | protein_coding | CACNA1S | No | No | 779 | B1ALM3 Q13698 |
TVIS10014316 | HBV | ENSG00000081248.13 | protein_coding | CACNA1S | No | No | 779 | B1ALM3 Q13698 |
TVIS30087325 | HIV | ENSG00000081248.13 | protein_coding | CACNA1S | No | No | 779 | B1ALM3 Q13698 |
TVIS30026316 | HIV | ENSG00000081248.13 | protein_coding | CACNA1S | No | No | 779 | B1ALM3 Q13698 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
Gene | CACNA1S |
---|---|
DrugBank ID | DB01054 |
Drug Name | Nitrendipine |
Target ID | BE0002355 |
UniProt ID | Q13698 |
Regulation Type | inhibitor |
PubMed IDs | 16675661; 1846597 |
Citations | Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4.@@Regulla S, Schneider T, Nastainczyk W, Meyer HE, Hofmann F: Identification of the site of interaction of the dihydropyridine channel blockers nitrendipine and azidopine with the calcium-channel alpha 1 subunit. EMBO J. 1991 Jan;10(1):45-9. |
Groups | Approved; Investigational |
Direct Classification | Dihydropyridinecarboxylic acids and derivatives |
SMILES | CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC |
Pathways | Nitrendipine Action Pathway |
PharmGKB | PA146096020 |
ChEMBL | CHEMBL475534 |